Panbela Therapeutics Valuation
Is X70 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Book vs. similares
Price-To-Book vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of X70 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de X70 para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de X70 para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for X70?
Other financial metrics that can be useful for relative valuation.
| What is X70's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$2.65m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does X70's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
T5O bioXXmed | 0.09x | n/a | €1.9m |
DBI Deutsche Biotech Innovativ | 1.4x | n/a | €985.2k |
CNW co.don | 1x | n/a | €6.5m |
2INV 2invest | 0.9x | n/a | €48.9m |
X70 Panbela Therapeutics | n/a | 46.1% | €2.6m |
Price-To-Book vs. similares: X70 tiene fondos propios negativos y un Ratio Price-To-Book (-0.7x) comparado con la media de sus homólogos (0.8x).
Price to Earnings Ratio vs Industry
How does X70's PE Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs. Industria: X70 tiene patrimonio negativo y un ratio Price-To-Book (-0.7x) comparado con la media de la industria European Biotechs (2.4x).
Price to Book Ratio vs Fair Ratio
What is X70's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.6x |
| Fair PB Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular el ratio justo de X70 Price-To-Book para análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.63 | €13.93 +2,111.2% | 66.7% | €23.22 | €4.64 | n/a | 2 |
| Apr ’25 | €0.59 | €159.34 +26,906.5% | 85.5% | €295.58 | €23.09 | n/a | 2 |
| Mar ’25 | n/a | €376.09 0% | 22.0% | €458.65 | €293.54 | n/a | 2 |
| Feb ’25 | n/a | €376.09 0% | 22.0% | €458.65 | €293.54 | n/a | 2 |
| Jan ’25 | n/a | €376.09 0% | 22.0% | €458.65 | €293.54 | n/a | 2 |
| Dec ’24 | n/a | €375.72 0% | 22.0% | €458.20 | €293.25 | n/a | 2 |
| Nov ’24 | n/a | €431.37 0% | 31.9% | €569.04 | €293.70 | n/a | 2 |
| Oct ’24 | n/a | €431.37 0% | 31.9% | €569.04 | €293.70 | n/a | 2 |
| Sep ’24 | n/a | €431.37 0% | 31.9% | €569.04 | €293.70 | n/a | 2 |
| Aug ’24 | n/a | €559.79 0% | 38.6% | €821.43 | €292.06 | n/a | 3 |
| Jul ’24 | n/a | €559.79 0% | 38.6% | €821.43 | €292.06 | n/a | 3 |
| Jun ’24 | n/a | €3,353.31 0% | 57.1% | €5,437.81 | €815.67 | n/a | 3 |
| May ’24 | n/a | €3,353.31 0% | 57.1% | €5,437.81 | €815.67 | n/a | 3 |
| Apr ’24 | n/a | €3,218.16 0% | 73.9% | €5,596.81 | €839.52 | €0.59 | 2 |
| Oct ’23 | n/a | €130,812.13 0% | 9.1% | €142,704.14 | €118,920.12 | n/a | 2 |
| Sep ’23 | n/a | €130,812.13 0% | 9.1% | €142,704.14 | €118,920.12 | n/a | 2 |
| Aug ’23 | n/a | €169,881.77 0% | 44.5% | €276,057.88 | €106,176.11 | n/a | 3 |
| Jul ’23 | n/a | €169,881.77 0% | 44.5% | €276,057.88 | €106,176.11 | n/a | 3 |
| Jun ’23 | n/a | €169,881.77 0% | 44.5% | €276,057.88 | €106,176.11 | n/a | 3 |
| May ’23 | n/a | €169,881.77 0% | 44.5% | €276,057.88 | €106,176.11 | n/a | 3 |
| Apr ’23 | n/a | €169,881.77 0% | 44.5% | €276,057.88 | €106,176.11 | n/a | 3 |
Pronóstico de los analistas: El precio objetivo es más de 20% superior al precio actual de la acción, pero no hay suficientes analistas que cubran el valor para determinar confianza estadística en el acuerdo.